Flecainide suppresses cardiac tachyarrhythmias including paroxysmal atrial fibrillation, supraventricular tachycardia and arrhythmic long QT syndromes (LQTS), as well as the Ca 2+ -mediated, catecholaminergic polymorphic ventricular tachycardia (CPVT). However, flecainide can also exert pro-arrhythmic effects most notably following myocardial infarction and when used to diagnose Brugada syndrome (BrS). These divergent actions result from its physiological and pharmacological actions at multiple, interacting levels of cellular organization. These were studied in murine genetic models with modified Na v channel or intracellular ryanodine receptor (RyR2)-Ca 2+ channel function. Flecainide accesses its transmembrane Na v 1.5 channel binding site during activated, open, states producing a use-dependent antagonism. Closing either activation or inactivation gates traps flecainide within the pore. An early peak I Na related to activation of Na v channels followed by rapid de-activation, drives action potential (AP) upstrokes and their propagation. This is diminished in pro-arrhythmic conditions reflecting loss of function of Na v 1.5 channels, such as BrS, accordingly exacerbated by flecainide challenge. Contrastingly, pro-arrhythmic effects attributed to prolonged AP recovery by abnormal late I NaL following gain-of-function modifications of Na v 1.5 channels in LQTS3 are reduced by flecainide. Anti-arrhythmic effects of flecainide that reduce triggering in CPVT models mediated by sarcoplasmic reticular Ca 2+ release could arise from its primary actions on Na v channels indirectly decreasing [Ca 2+ ] i through a reduced [Na + ] i and/or direct open-state RyR2-Ca 2+ channel antagonism. The consequent [Ca 2+ ] i alterations could also modify AP propagation velocity and therefore arrhythmic substrate through its actions on Na v 1.5 channel function. This is consistent with the paradoxical differences between flecainide actions upon Na + currents, AP conduction and arrhythmogenesis under circumstances of normal and increased RyR2 function.
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Introduction
Cardiac arrhythmias constitute an important clinical and public health problem. Pharmacological modes of action, effectiveness and specific indications of anti-arrhythmic agents are therefore of particular interest (Huang, 2017) . This is particularly so when they exert contrasting, beneficial, ineffective or even harmful actions dependent upon the particular physiological or clinical circumstances under which they are applied. The class Ic anti-arrrhythmic agent flecainide ((RS)-N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide); C 17 H 20 F 6 N 2 O 3 ) ( Figure 1A ) was derived from explorations of 2,5-bis(2,2,2-trifluoroethoxy) benzamide compounds as pharmaceutical candidates. Early studies in intact canine hearts demonstrated that flecainide markedly increased ventricular fibrillation thresholds following supraventricular beats and ventricular premature beats and slowed ectopic atrial and ventricular pacemakers. It also prolonged atrioventricular (AV) conduction (at plasma concentrations of 0.4 to 0.7 μg·mL À1 ) and overall excitation delay (at >6.5 μg·mL À1 ) (Hodess et al., 1979) . Standard microelectrode techniques attributed these findings to reductions in maximal rates of rise of the action potential (AP), (dV/dt) max , in the absence of stimulation. These became accentuated during stimulus trains with stimulus intervals <4800 ms over 20 to 50 beats in guinea pig ventricle even at normal resting potentials. Flecainide also produced negative steady-state shifts in the relationship between (dV/dt) max and membrane potential of possible clinical relevance in ischaemic states (Campbell and Vaughan Williams, 1983) .
In common with other anti-arrhythmic agents, flecainide also affected cardiac contractile activation processes, dosedependently decreasing peak left ventricular isovolumic pressure and peak isovolumic rate of pressure generation, (dP/dt) max , in intact rat hearts (Hoffmeister et al., 1987; Fernandes et al., 2014) . These findings correlated with decreased aequorin luminescence and isometric tension signals in isolated canine ventricular trabeculae and reduced L-type Ca 2+ current, I CaL , in isolated myocytes from the same ventricle (Kihara et al., 1996) . These findings translated to effects on peak isometric contractile force and maximal rates of force development and decline in human ventricular muscle (Lynch et al., 2013) . These results suggest multiple, potentially interacting, actions requiring analysis at the systems level, whose mechanisms and pharmacological implications are reviewed in this present article.
Anti-arrhythmic effects of flecainide
Initial clinical studies reported encouraging effects of flecainide on occurrences of premature ventricular or atrial contractions in arrhythmic patients while minimally altering their electrocardiographic (ECG) PR, QRS or QT intervals or producing other side effects (Somani, 1980) . The compound has a high bioavailability. Its amide group has a pKa of~9.3 (Liu et al., 2003) , and so, it is 99% protonated as a water soluble monovalent cation at physiological pH. Peak blood levels are reached 1 to 6 h after oral ingestion (Smith, 1985) . Its plasma half-life is 12 to 27 h (Padrini et al., 1993) . Subsequent reports similarly confirmed that even low (100 mg twice daily) flecainide doses reduced both triggering events represented by premature ventricular contractions (Abitbol et al., 1983) and substrate reflected in the appearance of ventricular tachycardia (VT) following programmed electrical stimulation, during Holter monitoring and electrophysiological testing (Somberg and Tepper, 1986) . Its pharmacokinetics permitted oral administration (Anderson et al., 1981; Pottage, 1983; Holmes and Heel, 1985) . Orally administered flecainide also suppressed premature ventricular complexes and VT (Anderson et al., 1981) and proved acceptable for long-term use (Meinertz et al., 1984) .
Figure 1
These findings led to the use of flecainide in preventing and treating ventricular ectopic events and tachycardias, paroxysmal atrial fibrillation (Anderson et al., 1989) and supraventricular tachycardia, including AV nodal re-entrant tachycardia and Wolff-Parkinson-White syndrome (Henthorn et al., 1991; Pritchett et al., 1991) . It was also beneficial for long QT syndromes, particularly the long QT syndrome type 3 (LQTS3), associated with gain-of-function mutations in Na v 1.5 channels (Shimizu and Antzelevitch, 1999) . Low-dose, oral flecainide shortened corrected QT (QTc) intervals and normalized repolarization T-wave patterns in LQTS3 patients with SCN5A-ΔKPQ mutations (Windle et al., 2001; Moss et al., 2005) , consistent with its application as a mutation-specific therapy for LQTS3 (Benhorin et al., 2000) . Flecainide was relatively free of adverse, particularly neurological and gastrointestinal, side effects at effective dose levels (Anderson et al., 1981; Pottage, 1983; Holmes and Heel, 1985) .
Pro-arrhythmic effects of flecainide: the CAST trial
Through its long history of clinical benefit, the use of flecainide has been shadowed by pro-arrhythmic consequences under some clinical circumstances, particularly in the presence of ischaemic or morphological changes. Ventricular tachyarrhythmias and severe bradycardia occur when its narrow therapeutic index is exceeded by frank overdose or with chronic cardiac disease. Such cases show increased PR and QRS intervals suggesting depressed conduction and signs and symptoms attributable to overt heart failure, likely to reflect acutely decreased myocardial contractility (Winkelmann and Leinberger, 1987 ). An early study reported that 7 of 152 patients showed pro-arrhythmic effects including VT or ventricular fibrillation over an~22 month period, similarly associated with increased PR intervals and widened QRS complexes rather than QTc prolongation (Nathan et al., 1984) . Additionally, in the Cardiac Arrhythmia Suppression Trial (CAST), antiarrhythmic therapy with encainide, flecainide or moricizine initially suppressed arrhythmia in 1727 of 2309 post-myocardial infarction patients with asymptomatic or mildly symptomatic ventricular arrhythmia during Holter recording. However, encainide or flecainide-treated patients showed a higher incidence (8.9%) of arrhythmic death than patients assigned to placebo (1.2%) over a 10 month follow-up (CAST Investigators, 1989; Echt et al., 1991; Greenberg et al., 1995) . Finally, flecainide has proved pro-arrhythmic in individuals suspected of having Brugada syndrome (BrS) where it can unmask its characteristic ECG findings, a fact used in its clinical diagnosis in equivocal cases (Gasparini et al., 2003; Wolpert et al., 2005; Meregalli et al., 2006) .
Na v channel activation and inactivation processes
These multifarious actions of flecainide under different clinical circumstances may reflect arrhythmias being multicellular phenomena. They involve triggering mechanisms formed by spontaneous electrophysiological events occurring independently of the normal cardiac pacing process. In addition, the presence of arrhythmic substrate in the form of further electrophysiological abnormalities could perpetuate this arrhythmic event. These depend upon the electrophysiological stability of cellular excitation involving the interacting properties of numerous channel types, alterations in AP conduction between myocytes and the effects of myocardial anatomy. Understanding the effects of flecainide therefore not only concerns its actions at the molecular level but also their systems-level consequences. It would then be necessary to consider interacting functional changes at the cellular, tissue and organ levels and to correlate these with the targeted clinical outcome. The following sections explore the extent to which these diverse actions of flecainide under various disease paradigms are accounted for by its actions upon multiple interacting cellular targets, of which the most prominent are the voltage-gated Na v ion channels.
The Na v channel function itself poses intrinsic complexities. First, it entails distinct activation and inactivation processes. Channel activation depends on movements of S4 α-helices predominantly in domains DI-III whose positive charges underly their voltage-sensing function (Catterall, 2012) . This process drives the rapid initial, phase 0 depolarization that activates the cardiac AP as well as its propagation to neighbouring and previously quiescent regions. Channel inactivation results from similar voltage-sensitive movement of the S4 α-helix in domain DIV, which drives pore occlusion by the cytoplasmic III-IV linker (Kühn and Greeff, 1999) . A further slow inactivation may involve further conformational changes in the α-subunit pore region (Ulbricht, 2005) . Secondly, the resulting inward Na + current, I Na , may include one or more current components, each with different kinetics. These might reflect either modulations in the function of individual cardiac Na v 1.5 channels or distinct channel subpopulations Saint, 2009 (Noble and Noble, 2006; Makielski, 2016) . Although I NaL shows a more negative (by À20 mV) voltage dependence in its activation properties , its channel conductance, mean open Note that as flecainide binds within the pore of the channel, the site has been visualized as a slice through the protein; this excludes some of the overlying helices. Hydrogen bond interactions (dashed red line) are predicted with IV-S6-phe. At Nav1.4, a cation-π interaction is seen at the same location (Ahern et al., 2008) . (R)-flecainide was generated ab initio using Chem3D Prov14.0 (CambridgeSoft, Cambridge, UK), energy minimized using the implemented MM2 force field and docked using GOLD Suite v5.3 (The Cambridge Crystallographic Data Centre, Cambridge, UK) with the GoldScore function and default settings. Amino acid sequences used in the ClustalW alignment are 4DXW and 4EKW taken directly from structures of bacterial sodium channels; r_brain II = P04775; h_Nav1.1 = NP_001189364; h_Nav1.2 = NP_001035232; h_Nav1.4 = NP_000325; h_Nav1.5 = NP_932173; hNav1.7 = ABI51981.
times and selectivity properties are otherwise identical to the remaining I Na . Increased I NaL influences AP duration and the refractory period. Finally, with repolarization to the resting potential, the Na v 1.5 channels recover their capacity for re-excitation, resulting in absolute and relative refractory periods. These correspond to the time intervals over which the channels either cannot be reexcited whatever the stimulus intensity, or require increased stimulus amplitudes for such re-excitation.
Molecular pharmacology of flecainide
Studies of clinically occurring Na v 1.5 channel variants showed that mutations in the IV-S6 helix were most commonly associated with altered responses to flecainide and overlapping interactions with other, similarly cationic and hydrophobic, local anaesthetics. They thus suggested that the flecainide binding site on Na v 1.5 channels is close to this region ( Figure 2 ) (Viswanathan et al., 2001; Liu et al., 2002 Liu et al., , 2003 Viswanathan and Balser, 2004; Fozzard et al., 2011) . Other amino acid substitution studies revealed that only two IV-S6 residues affected interactions of Na v 1.5 channels with anaesthetics (Ragsdale et al., 1994; Yarov-Yarovoy et al., 2002; Hanck et al., 2009) . In particular, unnatural amino acid mutagenesis showed that high-affinity binding of lignocaine highly depended upon cation-π interactions with phenylalanine-1759; it is possible that the positive charge of flecainide could similarly interact ( Figure 2A ) (Ahern et al., 2008) . Figure 2B illustrates this region by docking flecainide into a proteobacterial homologue of the Na v 1.5 channel (NavRh) . In this docked pose, flecainide occupies a hydrophobic cavity at the interface of adjacent subunits and makes contact with the important phenylalanine in IV-S6. In K + channels, including the K v 11.1 channels, flecainide may have similar binding sites that also overlap with binding sites for other ligands, such as the structurally related propafenone ( Figure 1B ). Binding is again heavily influenced by interactions with a phenylalanine residue in the S6 helix (Madeja et al., 2010; Melgari et al., 2015) . These effects appeared to be mediated by charged rather than uncharged flecainide accessing the channel from the cell interior. Studies of its effects on I KR from expressed K v 11.1 channels, containing a range of single site mutations, suggested that flecainide binds low in the inner channel cavity (Melgari et al., 2015) . These similarities suggest that flecainide binding is constrained even between receptor subtypes. Such shared sites of action are perhaps not surprising. Elsewhere, different members of the Cys-loop family of ligand-gated ion channels also share a common transmembrane binding site for anaesthetics (Forman et al., 1995; Nury et al., 2011) .
Na v channel antagonism by flecainide
Flecainide acts upon the activated, open, state of Na v 1.5 channels (Anno and Hondeghem, 1990; Nitta et al., 1992; Nagatomo et al., 2000) ( Figure 3A ), gaining access to a transmembrane binding site where it blocks the pore, and inhibits I Na (Liu et al., 2002 (Liu et al., , 2003 ( Figure 3B ). I Na inhibition takes place with a low affinity (IC 50 = 345 μM) during brief depolarizing steps. However, the affinity dramatically increases (IC 50 = 7.4 μM) with increasing stimulation frequency as expected for use-dependent binding. This usedependent antagonism occurs at concentrations as low as 0.5 μM and saturates at ≥50 μM flecainide (Nitta et al., 1992) . It is reflected in an increasing inhibition of I Na ( Figure 4A , left panel) and a consequent shift in the dependence of I Na inhibition towards lower flecainide concentrations under conditions of increasing pulsing frequency ( Figure 4A , right panel) (Penniman et al., 2010) . This accounts for progressive increases in AP refractory periods, decreases in (dV/dt) max and increases in action potential duration (APD) with increasing stimulus frequencies in hearts of a range of species ( Figure 4B ) (Wang et al., 1990) . Consistent with this, in a non-inactivating Na v 1.5 channel mutant, flecainide produced decays in I Na with a time course suggesting a simple pore blocking mechanism (K D = 11 μM). Once bound, flecainide reduces Na v channel open times (Grant et al., 2000) . Flecainide binding to channels then inactivated by sustained depolarization does not contribute to Na v channel inhibition (Nitta et al., 1992; Nagatomo et al., 2000; Liu et al., 2002; Wang et al., 2003) . Flecainide action was not enhanced with sustained depolarization producing channel inactivation (Ramos and O'Leary, 2004) . Flecainide does not directly bind to closed or inactivated Na v channels, but closing either the activation or the inactivation gate traps flecainide within the pore (Figure 3 C), slowing recovery of drug-bound channels at hyperpolarized voltages. Thus, flecainide slowed recovery of both rapidly inactivating (τ~81 s) and non-inactivating (τ~42 s) channels with hyperpolarization. The mutation of a conserved isoleucine, SCN5A-I1756C, within the pore forming region (DIV-S6), accelerated recovery of both rapidly inactivating (τ~12.6 s) and non-inactivating (τ~7.4 s) channels. These observations suggest that flecainide is trapped rather than tightly bound within the pore when channels are closed or inactivated (Ramos and O'Leary, 2004) .
Contrasting actions of flecainide in ion channel models for arrhythmia
Experimental studies suggest that some of the contrasting effects of flecainide reflect the differing mechanisms underlying arrhythmia in the particular models under study ( Figure 5 ). They suggest that flecainide exerts pro-arrhythmic effects upon arrhythmic substrate attributable to compromised AP activation and propagation resulting from a reduced peak I Na correspondingly compromising AP upstroke velocities, (dV/dt) max . This situation is likely in the BrS, whose commonest genetic accompaniment is an inherited loss-of-function in Na v 1.5 channels, associated with increased risks of potentially fatal ventricular arrhythmias particularly in middle aged (40-45 years) males (Brugada et al., 2002) . It has been modelled in isolated murine heterozygotic Na v 1.5 channel haplo-insufficient Scn5a +/À cardiac preparations (Papadatos et al., 2002) . These preparations replicated the clinically observed arrhythmic tendencies and attributed these to compromised AP conduction particularly following extrasystolic stimuli, findings that correlate with biophysical observations of a reduced peak I Na (Martin et al., 2011b (Martin et al., , 2012 . Flecainide challenge also reproduced clinical observations, as it increased these ventricular arrhythmic tendencies (Stokoe et al., 2007a; Martin et al., 2010; Matthews et al., 2013) . The altered balance between inward I Na and outward I to mediating early AP repolarization would also be expected to increase the likelihood of pro-arrhythmic phase II re-entry phenomena (Lukas and Antzelevitch, 1996) , although these would be made less likely as flecainide also increases effective refractory periods (Martin et al., 2011a) .
In contrast, flecainide exerts anti-arrhythmic effects under conditions associated with abnormal AP recovery, particularly when arising from increased I NaL . The open channel antagonist nature of flecainide action on Na v 1.5 channels could make it particularly effective on Na v channels showing prolonged dwell times, as with the increased I NaL in LQTS3. Patch-clamp studies on the HEK293 expression system demonstrated that flecainide exerted a more marked tonic and use-dependent I Na antagonism in Scn5a + /ΔKPQ than wild-type (WT). Scn5a + /ΔKPQ channels showed a greater use-dependent antagonism of both peak I Na and I NaL than WT channels. In both cases, flecainide preferentially inhibited I NaL (IC 50~1 9 vs. 44 μM) over peak I Na (IC 50~8 0 vs. 127 μM) (Nagatomo et al., 2000) . In LQTS3, both AP prolongation and increased arrhythmic tendency is attributed to increased late Na + current I NaL and a consequent persistent Na v channel opening. This thus provides a pro-arrhythmic exemplar distinct from arrhythmia arising from deficient peak I Na in BrS. This was accompanied by increased frequencies of early afterdepolarization events that could potentially act as arrhythmic triggers (Damiano and Rosen, 1984; Wang et al., 1995a; Thomas et al., 2008; Belardinelli et al., 2015 homeostasis further discussed below (Shryock et al., 2013) . The ventricles also showed altered transmural APD gradients across the ventricular wall potentially providing arrhythmic substrate (January and Riddle, 1989; Sabir et al., 2008; Horvath et al., 2013) . Both these abnormalities and their associated arrhythmic tendencies were abolished by flecainide (Stokoe et al., 2007b; Sabir et al., 2008) . This feature reproduces the clinically established, anti-arrhythmic effects of flecainide in LQTS3 (Windle et al., 2001; Moss et al., 2005) , further demonstrating that murine hearts can provide useful models for the human condition.
Occurrences of flecainide exerting pro-rather than antiarrhythmic effects in LQTS3 have also been reported.
Figure 4
Rate-dependent effects of flecainide on I Na , effective refractory period (ERP), V max and APD 95 in different species. (A) Left hand panel: superimposed Na + currents, I Na , recorded from HEK293 cells expressing hNa v 1.5 channels before and after application of 3 and 30 μM flecainide at different pulsing rates, illustrating use-dependent antagonism. Right hand panel: average steady-state I Na inhibition by flecainide at each pulsing rate expressed as a fraction of control current obtained in the absence of flecainide at that pulsing rate. IC 50 of flecainide at each pacing rate was determined from the Hill coefficient (adapted with permission from Figure 6A and B of Penniman et al., (2010) ). (B) The effects of flecainide on (from left to right) ERP, maximum rate of AP depolarization (V max ) and action potential duration at 95% recovery (APD 95 ) with changing basic cycle lengths (BCL) in guinea pig, rabbit, dog and human cardiac action potentials. With decreasing BCL, there was an increasing effect of flecainide on prolongation of both ERP and APD 95 , and a decreasing V max (figure adapted with permission from left hand panels of Figures 2-4 of Wang et al., (1990) ).
However, these were observed when LQTS3 phenotypic features were combined with abnormalities normally associated with a Na v 1.5 channel haplo-insufficient BrS, resulting in an overlap syndrome (Bezzina et al., 1999) . The latter has been modelled by murine Scn5a + /1795insD hearts.
In addition to the increased QTc intervals, bradycardia and bradycardic pauses expected from a LQTS3 phenotype, these showed increased PQ intervals and QRS durations suggesting slowed ventricular conduction. Patch-clamped ventricular myocytes correspondingly showed increased AP durations and increased I NaL . The voltage dependences of activation, of steady-state rapid or slow inactivation and of recovery from inactivation were of normal Na v 1.5 channels. In addition, reduced peak I Na and (dV/dt) max , correlated with multi-electrode recordings in Langendorff-perfused hearts revealing slowed conduction of excitation (Remme et al., 2006) . Overlap features were also shown by ageing Scn5a + / ΔKPQ (Guzadhur et al., 2010; Wu et al., 2012) . These findings could account for reports that flecainide produced STsegment elevation characteristic of BrS in some LQT3 patients, suggesting that this Na v channel antagonist could paradoxically be pro-arrhythmic in LQTS3 in the presence of accompanying conduction abnormalities (Priori et al., 2000) . Such dual phenotypes have also been attributed to myocardial heterogeneities (Clancy and Rudy, 2002) or simultaneous shifts in the inactivation characteristics of Na v 1.5 channels (Grant et al., 2002) . They could also arise from differences in the effects of flecainide upon inactivation gating. Both Scn5a + /1795insD and Scn5a + /ΔKPQ channels expressed in tsA-201 cells exhibited modified inactivation gating from the closed channel state. However, flecainide antagonized I NaL to different extents in the sequence WT < Scn5a + /ΔKPQ < Scn5a + /1795insD. Scn5a + /1795insD channels also showed delayed recoveries from inactivation further exacerbated by flecainide (Viswanathan et al., 2001) . Further complexities arise because Na v channels do not occur as isolated molecules in the plasma membrane but instead are anchored within larger, extended multicomponent complexes. Examples of such associated proteins include auxiliary Na v channel β subunits (Cusdin et al., 2010) , cytoskeletal proteins Huang, 2017) and other ion channels such as the inwardly rectifying K ir 2.1 channels (Willis et al., 2015) . These proteins can influence Na v channel gating behaviour both directly through protein-protein contacts and indirectly by affecting surface expression and trafficking (Abriel and Kass, 2005; Cusdin et al., 2008; Abriel et al., 2015) .
Relatively little attention has been paid to how this supramolecular channel clustering could influence flecainide pharmacology. To our knowledge, the only example where such effects on flecainide behaviour were studied is the case of the auxiliary Na v channel β3 subunit, the product of the Scn3b gene (Hakim et al., 2010) . The β3 subunit is expressed in heart and modulates gating of Na v 1.5 channels (Yu et al., 2005) . Patch-clamped Scn3b À/À murine cardiomyocytes showed reduced I Na , most likely reflecting reduced trafficking of Na v 1.5 channels to the surface membrane. This was combined with negative shifts in Na v 1.5 channel inactivation characteristics that would be expected to reduce
Figure 5
Feed-forward effects of flecainide attributable to its actions on Na v 1.5 channels. In this hypothesis, flecainide reduces peak, I Na , thereby reducing AP conduction velocity, exacerbating pro-arrhythmic conditions arising from loss of function in Na v 1.5 channels, occurring in conditions such as BrS. In contrast, its reduction of late, I NaL , would be anti-arrhythmic in conditions associated with gain of function in Na v 1.5 channels, increasing I NaL and prolonging AP duration such as LQTS. The inhibitory effect of flecainide on Na v 1.5 channels also increases triggering threshold. (Namadurai et al., 2015) . Curiously however, in Scn3b À/À hearts, flecainide produced reduced arrhythmic incidences combined with prolonged refractory periods and shortened APDs (Hakim et al., 2010) . This is in direct contrast to its effects in Scn5a +/À mice (see above). The reasons for this difference are unclear, but they further confirm suggestions that flecainide exerts dual pro-and anti-arrhythmic actions through effects on both conduction and refractoriness. Thus, in the case of Scn5a +/À hearts, the negative conduction velocity effects predominate in producing arrhythmia exacerbated by flecainide. In the case of LQTS3, refractoriness and recovery effects predominate in producing arrhythmia reduced by flecainide. The presence or absence of β3 subunits may differentially modify these two competing effects so that an anti-arrhythmic effect predominates. How this might work is currently unknown and will probably require detailed structural insights into how the β3 subunit interacts and modulates the Na v 1.5 channel α subunit. The β3 subunit contains a single extracellular immunoglobulin domain, a single-pass transmembrane domain and an intracellular domain and interacts with Na v 1.5 channels through both its extracellular and intracellular domains (Namadurai et al., 2015) . It is striking however that neither of these two interaction sites are close to the flecainide binding site on Na v 1.5 channels ( Figure 2B ). This suggests that the β3 subunit most likely modulates the effects of flecainide on Na v 1.5 channels indirectly, either by affecting channel opening probability or by its known effects on oligomerization of Na v 1.5 channels (Namadurai et al., 2014 (Namadurai et al., , 2015 .
K + channel antagonism by flecainide
Flecainide also acts on voltage-gated K + channels (Figure 6 ). At <10 μM, it inhibited the rapid K + current, I KR , tails that followed voltage clamp pulses to +30 mV in the HEK293 expression system. The effect was most noticeable in the steepest part of the I KR (carried by K v 11.1 channels, hERG) activation curve reflecting a voltage-dependent inhibition consistent with a rapid open channel state I KR antagonism similar to that described for I Na (Paul et al., 2002) . Flecainide (>10 μM) also inhibits rapid transient outward (K v 4.2 channels) currents, I tof , in both native cells (Slawsky and Castle, 1994) and heterologous expression systems (Rolf et al., 2000) , to extents increasing with channel inactivation and consistent with its higher affinity for the inactivated state of K v 4.2 channels (Wang et al., 1995b) . Finally, flecainide (~100 μM) inhibits the ultrarapid delayed rectifier (K v 1.5 channels) current, I Kur (Tamargo et al., 2004; Herrera et al., 2005) .
Anti-arrhythmic effects of flecainide in CPVT
More recently, flecainide proved to exhibit potential therapeutic efficacy in the Ca 2+ -mediated catecholaminergic
Figure 6
Flecainide actions on voltage-gated K v channel subtypes. Initial findings that flecainide prevented ventricular arrhythmia in two patients with respective CASQ2 and RyR2 mutations in exercise stress tests suggested a mechanism involving reduced triggering activity (Watanabe et al., 2009) . These clinical effects were corroborated by further case reports in which flecainide was added to prior conventional β-adrenoceptor antagonist therapy (Biernacka and Hoffman, 2011; Pott et al., 2011; Jacquemart et al., 2012; Mantziari et al., 2013; Wangüemert-Pérez et al., 2014) .
polymorphic ventricular tachycardia (CPVT
Combination therapy using a β-adrenergic antagonist and flecainide partially or completely suppressed ventricular arrhythmias in 76% of one CASQ2 and 32 RYR2 mutation carriers with intractable CPVT (Van Der Werf et al., 2011) . It also completely suppressed exercise-induced ventricular arrhythmia in all of 10 CASQ2-D307H patients who were experiencing exercise-induced events on β-blocker therapy alone or in combination with a Ca 2+ channel antagonist. This remission was maintained in 8 of the 10 patients over añ 15 month follow-up period (Khoury et al., 2013) . Furthermore, addition of flecainide completely prevented ventricular arrhythmias during exercise testing and over long-term follow-up in 7 of 12 patients with RYR2, CASQ2 or KCNJ2 genotype-negative CPVT resistant to conventional β-blocker therapy (Watanabe et al., 2013) .
Flecainide monotherapy was pursued in patients carrying RyR2 mutations in which one patient did not tolerate β-blockers and seven other patients were switched to flecainide monotherapy from combined therapy. Monotherapy with flecainide proved more effective or equal to β-blocker monotherapy, while combination therapy only proved more successful in two of the eight patients over añ 37 month follow-up period (Padfield et al., 2016) . The paediatric CPVT phenotype is often more severe than the adult presentation (Hayashi et al., 2009) . Flecainide was used in 24% of patients in a retrospective paediatric (<19 years of age) cohort study of 226 CPVT patients. Treatment failure never occurred in any adherent patient receiving optimal doses of both flecainide and β-blocker. Flecainide monotherapy was used in a limited number of five patients. Results then compared well with results from β-blockers, implantable cardioverter defibrillators and left cardiac sympathetic denervation. All these cases showed suppression of exercise induced events; 78% remained asymptomatic, and there was no mortality on follow-up (Roston et al., 2015) . Pro-arrhythmic effects of flecainide of the kind observed in BrS have not been observed in the context of CPVT.
Nevertheless, given the underlying catecholaminergic trigger for CPVT, their efficacy and wide therapeutic window, the first line of current therapy continues to utilize β-blocker monotherapy. However, β-blockers are not well tolerated or do not have an adequate therapeutic efficacy in as many as 30% of cases. These are often the younger, healthier patients. In these situations, the addition of flecainide as a combined therapy may prove more effective. Thus, flecainide is an appealing therapeutic addition to traditional β-blocker monotherapy, particularly in patients resistant to such therapy or requiring high-dose β-blockers. Adverse side effects might then be reduced through the use of smaller doses of two as opposed to a larger dose of a single pharmacological agent. Recent reports have progressed to introduce flecainide monotherapy in particular cases, with encouraging preliminary results. Flecainide monotherapy emerges as an available and effective next step, where β-blockers are not tolerated or ineffective. However, the current data relies on limited studies. Further investigation is required to conclusively assess flecainide monotherapy as an earlier line of treatment, given its narrow therapeutic window (Priori et al., 2013; Lieve et al., 2016) .
Indirect actions of flecainide on Ca 2+ -mediated triggering of arrhythmia
Flecainide also acts upon Ca 2+ -mediated arrhythmia, as exemplified by its use in the management of CPVT outlined above. This action may involve cellular-level interactions following its effects upon its primary molecular targets. Thus, two contrasting groups of observations both suggest indirect, feed-forward effects arising from its Na v channel antagonism and additionally implicate such actions in increased thresholds for triggered pro-arrhythmic activity.
In the first of these, flecainide pretreatment reduced incidences of sustained VT in RyR2-R4496C +/À mice studied by ECG telemetry, following adrenaline and caffeine challenge, from 70 to 8%. In isolated intact regularly paced (1 Hz) RyR2-R4496C +/À ventricular myocytes, isoprenaline
(1 μM) increased the amplitudes and accelerated the decays of spontaneous Ca 2+ transients and increased SR Ca 2+ load.
Permeabilized

RyR2-R4496C
+/À ventricular myocytes similarly demonstrated greater spontaneous Ca 2+ spark and wave activity than WT, particularly following isoprenaline challenge. Both these groups of Ca 2+ release phenomena persisted with flecainide (6 μM) challenge but were abolished by tetracaine ( Figure 1C ). Patch-clamped RyR2-R4496C
myocytes showed increased incidences of DADs and triggered activity with isoprenaline challenge. Flecainide reduced the occurrences of the triggered but not the DAD activity. These findings suggest flecainide actions attributable to its primary effects on Na v channel availability (Liu et al., 2011) . Secondly, flecainide (5 μM) reduced Ca 2+ spark and wave frequency, but not amplitude, waveform or associated levels of SR Ca 2+ loading in superfused, regularly paced healthy adult rat ventricular myocytes. However, tetrodotoxin, propafenone ( Figure 1B ) and lignocaine ( Figure 1D ) exerted similar actions (Sikkel et al., 2013) . These agents, all known to decrease I Na , and correspondingly reducing [Na + ] i , could thereby decrease [Ca 2+ ] i , through an enhanced reverse mode action of the NCX (Bers and Ellis, 1982; Eisner et al., 1984 (Hilliard et al., 2010) , with efficacies and potencies varying with channel activity (Savio-Galimberti and Knollmann, 2015) . Antagonism of open-state RyR2 channels may be specific to flecainide in contrast to the prolonged RyR2 channel closure produced by tetracaine (Huang, 1997; Hilliard et al., 2010; Huang et al., 2011) . Flecainide would then produce optimal antagonist actions in association with the increased activity of 'leaky' CPVT as opposed to WT RyR2 channels. Lipid bilayer studies reported that flecainide antagonized WTRyR2 channel opening with a half maximal inhibitory concentration (IC 50 ) of~15 μM with the high luminal [Ca 2+ ] expected to produce spontaneous SR Ca 2+ release (Watanabe et al., 2009) , reducing RyR2 open probabilities, particularly when the channels were in the open state (Hilliard et al., 2010) . The IC 50 values for flecainide action became progressively lower as bilayer voltage became more positive in a direction that would increase cation current flow from the cytoplasmic to the luminal side of the bilayer. The latter would correspond to a direction opposite to that expected with spontaneous Ca 2+ release (Watanabe et al., 2009; Hilliard et al., 2010; Mehra et al., 2014) . Conversely, IC 50 values increased 1000-fold to mM levels at negative bilayer potentials that would result in a current flow from the lumen to the cytoplasm. This would correspond to a direction aligned with that expected for spontaneous Ca 2+ release (Mehra et al., 2014) . Similarly in WT RyR2 channels exposed to EMD41000, consequently with high open probabilities, flecainide (10 μM) reduced cytoplasmic-to-luminal currents, but not the luminal-to-cytosolic current even at higher (50 μM) concentrations (Bannister et al., 2015) . The fully charged (QX-FL) and neutral (NU-FL) flecainide derivatives were less effective antagonists of cytoplasmic-to-luminal currents and similarly did not affect luminal-to-cytosolic current (Bannister et al., 2016) . Nevertheless, flecainide may show multiple modes of inhibition of the RyR2 channels (Hwang et al., 2011; Mehra et al., 2014) . Both cytoplasmic and luminal flecainide induced two modes of inhibition respectively associated with millisecond and second time-scale channel closures under conditions of near-maximal RyR2 channel activation. The latter was achieved by the presence of 100 μM cytoplasmic Ca 2+ and 2 mM cytoplasmic ATP. Reducing cytoplasmic free [Ca 2+ ] to 100 nM, adding 1 mM free [Mg 2+ ] and increasing (cytoplasmic-luminal) membrane potential decreased the flecainide IC 50 . Some of the differing observations may also reflect use of differing, native sheep or recombinant human, RyR2, preparations, levels of associated proteins, ionic conditions and directions of charge flow in the different reports. Finally, flecainide could potentially bind calmodulin or other intermediary proteins with differing effects from those resulting from its direct binding to RyR2 channels (Smith and MacQuaide, 2015) . In Casq2 À/À mice, flecainide pre-administration reduced incidences of ventricular arrhythmic patterns such as bigeminy and biventricular tachycardia (Watanabe et al., 2009 Tetracaine contrastingly exerted similar effects in both groups. Furthermore, increasing Ca 2+ spark and wave activity in WT myocytes by caffeine increased the potencies of both flecainide and propafenone but not of tetracaine. Other class I antiarrhythmic drugs, such as lignocaine, mexiletine and quinidine ( Figure 1D-F) did not exhibit such antiarrhythmic efficacy in CPVT models (Savio-Galimberti and Knollmann, 2015) . This difference was attributed to the different extents to which these test agents antagonized RyR2-mediated SR Ca 2+ release (Hwang et al., 2011) .
Additionally, in both WT and RyR2-R4496C +/À murine Purkinje cells, flecainide suppressed spontaneous Ca 2+ release events as effectively as did tetracaine (Kang et al., 2010) . The scheme in Figure 5 summarizes the above feedforward effects of flecainide ultimately arising from its actions on Na v 1.5 channels. Its action in reducing peak, I Na , would result in a reduction of action potential (AP) conduction velocity. This would exacerbate arrhythmia in BrS as the phenotype in this variant is attributable to a loss of function in Na v 1.5 channels. In contrast, its actions in reducing late, I NaL , would reduce arrhythmia in LQTS3 as this phenotype results from a gain of function in Na v 1.5 channels which prolongs AP duration. Inhibition of Na v 1.5 channels also increases triggering threshold. Finally, a reduced Na (Casini et al., 2009 ). This could reflect direct Ca 2+ actions at an EF hand motif in the C-terminal region of Na v 1.5 channels (Wingo et al., 2004 and may also enhance slow Na + current inactivation (Tan et al., 2002) . RyR2-P2328S mice demonstrated isoprenaline-induced arrhythmic episodes resembling CPVT in ECG studies (Zhang et al., 2013) . Their intact isolated Langendorff-perfused hearts showed pro-arrhythmic atrial and ventricular triggering and arrhythmic events associated with altered Ca 2+ homeostasis during monophasic action potential recordings King et al., 2013b; Zhang et al., 2013) . In addition, they showed arrhythmic substrate resulting from delayed AP conduction. Atrial multi-electrode array, and ventricular micro-electrode recordings following isoprenaline challenge, showed pro-arrhythmic reductions in conduction velocity compared with WT. Intracellular microelectrode AP recordings showed correspondingly reduced maximum rates of depolarization (dV/dt) max (King et al., 2013b; Zhang et al., 2013) . These changes could be attributed to (a) chronically down-regulated expression of Na v 1.5 channels, demonstrated in RyR2-P2328S ventricles (Ning et al., 2016) , and (b) acute actions of increased [Ca 2+ ] i upon Na v 1.5 channel function.
Loose-patch clamp recordings demonstrated reduced peak I Na in whole isolated RyR2-P2328S compared with WT atria to extents comparable with those reported in Nav1.5 channel-haploinsufficent Scn5a +/À hearts (King et al., 2013a; Salvage et al., 2015) ( Figure 6A , left traces). These conduction abnormalities could not be attributed to either fibrotic change or altered connexin although it produced consistently anti-arrhythmic effects in RyR2-P2328S atria (Salvage et al., 2015) . Multi-electrode recording array studies demonstrated marked conduction slowing in RyR2-P2328S compared with WT atria. Flecainide reduced conduction velocity and indicators of AP upstroke velocity in WT hearts but did not do so in RyR2-P2328S hearts ( Figure 7B , left panel). RyR2-P2328S atria similarly showed a reduced peak I Na compared with WT ( Figure 7A , left panel). However, whereas 1 μM flecainide reduced peak I Na in WT atria, it rescued the previously reduced peak I Na in RyR2-P2328S atria to magnitudes indistinguishable from untreated WT ( Figure 7A , centre panels) while further increases to 5 μM flecainide inhibited I Na in common with effects on WT ( Figure 7A , right panels). Effective refractory periods were similar in untreated RyR2-P2328S and WT atria but were increased in flecainide-treated RyR2-P2328S ( Figure 7B , centre panel). As a result, flecainide shortened AP wavelength as computed from the product of conduction Cardiac actions of flecainide velocity and refractory period in WT in a direction towards increased arrhythmic substrate. In contrast, flecainide increased AP wavelength in RyR2-P2328S hearts consistent with its observed anti-arrhythmic effects ( Figure 7B , right panel) (Salvage et al., 2015) . Figure 8 summarizes these effects of flecainide upon arrhythmic substrate in terms of a hypothesis invoking RyR2-P2328S as a primary pharmacological target in addition to Na v 1.5 channels. It represents an increased RyR2-mediated SR Ca 2+ leak associated with the RyR2-P2328S variant as exerting down-regulatory effects upon Na v channel expression or function, thereby compromising AP conduction and potentially producing arrhythmic substrate. Flecainide is suggested to reduce the RyR2-mediated SR-Ca 2+ leak. This would drive a feedback rescue of the compromised function of Na v 1.5 channels, restoring I Na and thereby rescuing AP conduction. This would account for a net reduction in the arrhythmic substrate associated with the RyR2-P2328S mutation. These findings would be consistent with dual Na v 1.5 and RyR2-Ca 2+ channel blocking effects of flecainide and propafenone ( Figure 1A, B) , in contrast to selective effects of tetracaine ( Figure 1C) , and lignocaine and mexiletine ( Figure 1D ,C) on RyR2 and Na v 1.5 channels respectively, in turn consistent with patterns represented by their comparative chemical structures.
Summary and conclusions
The class Ic anti-arrhythmic agent flecainide shows both pro-and anti-arrhythmic actions depending on clinical and experimental circumstances. Flecainide therapy had initially been introduced to suppress cardiac tachyarrhythmias including paroxysmal atrial fibrillation, supraventricular tachycardia and arrhythmic LQTS. It subsequently proved useful in the management of Ca 2+ -mediated arrhythmias exemplified by CPVT. However, the CAST trial reported its pro-arrhythmic effects following myocardial infarction. In addition, proarrhythmic effects of flecainide have been used in diagnostic tests for BrS.
These divergent actions may reflect physiological and pharmacological actions of flecainide at multiple, interacting levels of cellular organization. There are also complexities in the interactions of flecainide with its primary target, the Na v 1.5 channels, as well as other possible cellular targets, in particular the RyR2-Ca 2+ release channels. Nevertheless, flecainide appears to act specifically through accessing a cytoplasmic binding site on Na v 1.5 channels in their activated, open state. This results in a use-dependent antagonism. It also acts on other, K v and RyR2-Ca 2+ release channels, but the resulting antagonism appears similarly to involve open channel block. Closing either the activation or the inactivation gates in the Na v 1.5 channel traps flecainide within its pore. Na v channel function itself involves an activation, which triggers the action potential upstroke and inactivation that influences both recovery from excitation and the refractory period. An early peak I Na related to Na v channel activation followed by rapid de-activation drives AP upstrokes and propagation. Peak I Na is diminished in pro-arrhythmic conditions reflecting loss of function in Na v 1.5 channels in experimental genetic exemplars for BrS. Experimental data
Figure 8
Feed-backward effects of flecainide on arrhythmic substrate attributable to its possible actions on RyR2-Ca 2+ release channels. A model invoking RyR2-P2328S channels as a primary pharmacological target for flecainide, in addition to Na v 1.5 channels, may account for its effect in diminishing arrhythmic substrate. Increased RyR2-mediated SR Ca 2+ leak, associated with RyR2-P2328S, down-regulates Na v channel expression or function, compromising AP conduction and potentially producing arrhythmic substrate. Reduction of the RyR2-mediated SR-Ca 2+ leak by flecainide rescues the compromised function of Na v 1.5 channels, restoring I Na and thereby AP conduction and reduces arrhythmic substrate.
confirms predictions that these conditions would be exacerbated by the inhibition of Na v 1.5 channels, following flecainide challenge. In contrast, the experimental data demonstrate that pro-arrhythmic phenotype effects attributed to abnormalities in AP recovery, due to increased I NaL following the gain-of-function modifications in Na v 1.5 channels, in LQTS3 are reduced by flecainide. 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015 /16 (Alexander et al., 2015a ).
